Freeline Therapeutics Holdings plc (FRLN)
Chart Events
Performance Outlook
| Previous Close | 0.8487 |
| Open | 0.8373 |
| Bid | 0.8602 x 900 |
| Ask | 0.9094 x 800 |
| Day's Range | 0.8373 - 0.9300 |
| 52 Week Range | 0.6500 - 15.4000 |
| Volume | |
| Avg. Volume | 191,267 |
| Market Cap | 31.875M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0260 |
| Earnings Date | Nov 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
- GlobeNewswire
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022. The presentation will provide safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial, which aims to confirm the FLT180a dose and immune
- GlobeNewswire
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen Cohort one efficacy and safety data to be presented at ISTH Congress in July Start-up activities for pivotal Phase 3 trial on track to begin in H1 2023 LONDON, June 14, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has begun dosing the second cohort
- GlobeNewswire
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggregate of 270,000 and 191,850 of the Company’s ordinary shares, respectively. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq List
